Screening strategies and predictive diagnostic tools for the development of new-onset diabetes mellitus after transplantation: an overview

Phuong-Thu T Pham¹
Kari L Edling²
Harini A Chakkera³
Phuong-Chi T Pham⁴
Phuong-Mai T Pham⁵

¹Department of Medicine, Nephrology Division, Kidney Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ²Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ³Department of Medicine, Nephrology Division, Kidney Transplant Program, Mayo Clinic Hospital, Phoenix, AZ, USA; ⁴Department of Medicine, Nephrology Division, UCLA-Olive View Medical Center, Sylmar, CA, USA; ⁵Department of Medicine, Greater Los Angeles, Veterans Administration Health Care System, CA, USA

Abstract: New-onset diabetes mellitus after transplantation (NODAT) is a serious and common complication following solid organ transplantation. NODAT has been reported in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Limited clinical studies in liver, heart, and lung transplants similarly suggested that NODAT has an adverse impact on patient and graft outcomes. Early detection and management of NODAT must, therefore, be integrated into the treatment of transplant recipients. Studies investigating the best screening or predictive tool for identifying patients at risk for developing NODAT early after transplantation, however, are lacking. We review the clinical predictive values of fasting plasma glucose, oral glucose tolerance test, and A1C in assessing the risk for NODAT development and as a screening tool. Simple diabetes prediction models that incorporate clinical and/or metabolic risk factors (such as age, body mass index, hypertriglyceridemia, or metabolic syndrome) are also presented.

Keywords: new-onset diabetes after transplantation, impaired fasting glucose, impaired glucose tolerance, oral glucose tolerance test, NODAT screening, diabetes prediction models

Introduction
The development of diabetes mellitus after kidney transplantation attributed to steroid use was first reported by Starzl in 1964,¹ and subsequently recognized as a complication of kidney transplantation in the 1970s. New-onset diabetes after solid organ transplantation associated with the use of immunosuppressive therapy (eg, steroids, cyclosporine, tacrolimus, sirolimus, and everolimus) has now been well described. Over the years, it has undergone changes in nomenclatures including steroid diabetes, posttransplant diabetes mellitus, new-onset diabetes mellitus, transplant-associated hyperglycemia, and most recently, new-onset diabetes after transplantation (NODAT). NODAT is a complex metabolic disorder characterized by a relative or absolute impairment in insulin secretion, along with varying degrees of peripheral insulin resistance. In essence, NODAT resembles type 2 diabetes and the diagnosis may be delayed or unrecognized. Indeed, over the years, the precise incidence of NODAT has been difficult to determine due to the lack of standard criteria defined for the condition. In 2003, the International Expert Panel consisting of experts from both the transplant and diabetes fields set forth the International Consensus Guidelines for the diagnosis and management of NODAT.²³ It was recommended that the definition and diagnosis of NODAT be based on the definition of diabetes mellitus and impaired glucose tolerance (IGT) described...
by the World Health Organization (WHO). It is noteworthy that while the 2003 International Consensus Guidelines defined normal fasting plasma glucose (FPG) as a plasma glucose of <110 mg/dL (6.1 mmol/L), the 2003 American Diabetes Association (ADA) expert committee had lowered the diagnostic threshold for impaired FPG to ≥100 mg/dL (5.6 mmol/L). The 2010 updated ADA consensus report included an A1C level of ≥6.5% as an alternative diagnostic criterion for diabetes mellitus in the general population based on the observed association between A1C level and the risk for future development of retinopathy. The current WHO and ADA guidelines for the diagnosis of prediabetic states (impaired fasting glucose [IFG] and IGT) and diabetes mellitus are provided in Table 1.

Studies in the general population have demonstrated that individuals with IFG, IGT, and/or an A1C value between 5.7% to 6.4% are at increased risk for future development of diabetes. Similar to the nontransplant settings, impaired glucose metabolism in the pre- and/or posttransplant period has been suggested to be a predictive risk factor for the development of NODAT. However, studies investigating the best screening or predictive tool for identifying patients at risk for developing NODAT early after transplantation are lacking. In this article, an overview of the literature on the utilization of currently available glycemic tests to predict or detect subclinical NODAT are discussed. Simple diabetes-prediction models that incorporate clinical and/or laboratory risk factors are also presented, followed by the authors’ perspective on the utility of various glycemic tests and diabetes-prediction models in the screening and diagnosis of NODAT.

**Table 1** WHO and ADA criteria for the diagnosis of diabetes mellitus

| Criteria for the diagnosis of DM |
|----------------------------------|
| Any one of the following: |
| 1. Classic symptoms of DM + random PG concentrations ≥ 200 mg/dL (11.1 mM) |
| 2. FPG ≥ 126 mg/dL (7.0 mM). Fasting is defined as no caloric intake for ≥8 hours |
| 3. 2-hour PG ≥ 200 mg/dL (11.1 mM) during an OGTT |
| 4. A1C ≥ 6.5% |

In the absence of unequivocal hyperglycemia accompanied by acute metabolic decompensation, criteria 2–4 must be confirmed by repeat testing on another day.

**Criteria for normal FPG and IFG or IGT**

- **FPG**
  - WHO criteria: FPG < 110 mg/dL (6.1 mM) = normal fasting glucose
  - FPG ≥ 110 mg/dL (6.1 mM) and < 126 mg/dL (7.0 mM) = IFG
  - 2003 ADA consensus:
    - FPG < 100 mg/dL (5.6 mM) = normal fasting glucose
    - FPG ≥ 100 mg/dL (5.6 mM) and < 126 mg/dL (7.0 mM) = IFG
  - OR
  - **OGTT**
    - 2-hour PG < 140 mg/dL (7.8 mM) = normal glucose tolerance
    - 2-hour PG ≥ 140 mg/dL (7.8 mM) and < 200 mg/dL (11.1 nM) = IGT

**Prediabetic states based on A1C level**

2010 ADA consensus: 5.7%–6.4%

**International expert committee:** 6.0%–6.4%

**Notes:** *Classic symptoms of DM include polyuria, polydipsia, and unexplained weight loss; *OGTT: the test should be performed as described by WHO, using a glucose load containing equivalent of 75 g anhydrous glucose dissolved in water; *A1C should be performed using a method certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized to the Diabetes Control and Complications Trial (DCCT) reference assay.

**Abbreviations:** WHO, World Health Organization; ADA, American Diabetes Association; DM, diabetes mellitus; PG, plasma glucose; FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test.

**Literature overview on the utility of FPG, A1C, and/or an oral glucose tolerance test**

The utility of FPG and OGTT in the prediction of NODAT development and as a screening tool

Glycemic testing in the early posttransplant period (fifth posttransplant day) Kuyper et al4 evaluated the utility of determining FPG levels and performing an oral glucose tolerance test (OGTT) in the early posttransplantation period for the prediction of NODAT development. The 2003 ADA criteria were used to define IGT, IFG, and diabetes mellitus. NODAT was defined as the uninterrupted need for glucose-lowering therapy for at least 3 months following transplantation. Renal allograft recipients with pre-existing diabetes mellitus were excluded from the study. All patients in the study completed an OGTT 5 days after transplantation, as stipulated by the WHO. In total, 359 eligible de novo renal transplant recipients were enrolled in the study. At a mean follow-up of 42.8 ± 16.9 months, 64 patients (17.8%) had developed NODAT. A normal (vs diabetic) OGTT at 5 days after transplantation was associated with a reduced risk of NODAT (odds ratio, 0.03; P = 0.0002). A similar risk reduction was conferred by a normal (vs diabetic) FPG level on day 5 (odds ratio, 0.06; P ≤ 0.0001). The OGTT on day 5 had better sensitivity (93.4% vs 21.6%) and a higher negative predictive value (97.6% vs 89.1%) than FPG test on day 5, but poorer specificity (71.9% vs 97.6%) and a lower positive predictive value (47.2% vs 61.5%). For transplant recipients who developed NODAT very early following transplantation, the concern arose that the OGTT on day 5 served merely as a diagnostic rather than a predictive
tool. However, a multivariate analysis involving only those who developed NODAT 2 or more weeks after the OGTT revealed a similarly significant association between a normal OGTT and a reduced risk for “delayed” NODAT. The results of the study suggested that a normal FPG (vs diabetic) and a normal OGTT (vs diabetic) at 5 days after transplantation seem to identify recipients at reduced risk for NODAT, at least among white subjects (91.4% of the study population were white, 1.4% were black, and Hispanics were absent). These findings remain to be validated in patients of other ethnicities.⁵

A Spanish study by Rodrigo et al⁶ also examined the predictive value of a fifth-day posttransplantation FPG. Of 282 previously nondiabetic patients, 46 (16.3%) developed NODAT by the 1-year follow-up. A fifth day FPG ≥ 126 mg/dL was associated with a more than fourfold increase in NODAT risk (relative risk, 4.784; 95% confidence interval [CI]: 2.121–10.788; P = 0.002). The positive and negative predictive value of a fifth day FPG ≥ 126 mg/dL for predicting NODAT at 1-year were 40% and 89.4%, respectively. The negative predictive value of nearly 90% suggested that a nondiabetic FPG may identify patients who are at lower risk for developing NODAT and therefore require less intensive screening in the future.

Glycemic testing after the first 6 months posttransplantation

Armstrong et al⁷ were among the first to examine the predictive power of FPG with respect to 2-hour blood glucose. A total of 200 previously nondiabetic renal transplant recipients who were more than 6 months posttransplantation underwent a standard 2-hour OGTT. Patients with FPG < 126 mg/dL (7.0 mmol/L; n = 188) underwent an OGTT. Receiver-operating characteristics (ROC) analyses were used to evaluate the optimal level of FPG that was predictive of NODAT (2-hour blood glucose ≥ 200 mg/dL; 11.0 mmol/L) and IGT (2-hour blood glucose of 140–200 mg/dL or 7.8–11.0 mmol/L). Forty-two percent of study subjects were found to have an abnormal OGTT (NODAT in 12% and IGT in 30%). The optimal FPG that was predictive of NODAT was 101 mg/dL (5.6 mmol/L; area under the curve, 0.70; sensitivity, 64%; specificity, 67%; positive predictive value, 20%; negative predictive value, 93%). The optimal FPG that was predictive of IGT was less well defined (area under the curve, 0.54). The prevalence of NODAT was higher by OGTT than by FPG alone (17% vs 6%; P < 0.0001). However, it is noteworthy that more than 80% of the study population was white. Inclusion of more patients with diverse ethnic background might have altered the reported prevalence of NODAT and IGT. Nonetheless, results from the study suggested that FPG may not be the optimal screening or diagnostic tool for NODAT or IGT due to its lack of sensitivity and specificity. Hence, the authors proposed that OGTT should be considered as a routine screening test in all renal transplant recipients.

In a prospective study designed to evaluate the value of OGTT for risk-stratifying patients for NODAT, Sharif et al⁸ demonstrated that among 122 renal transplant recipients without diabetes who had two FPG level measurements within the range of 100–125 mg/dL (5.6–6.9 mmol/L) more than 6 months after transplantation, OGTT revealed that 10% had overt diabetes mellitus, 9% had IGT alone, 18% had IFG alone (all defined by WHO criteria), and 14% had combined IFG and IGT. In agreement with most studies, this study demonstrated that FPG underestimates the prevalence of NODAT and IGT and suggested the routine use of OGTT in risk stratifying renal transplant recipients for the development of NODAT.

The utility of FPG and A1C in the prediction of NODAT development and as a screening tool

Hoban et al⁹ first described the utility of A1C in the detection of subclinical NODAT in recipients of kidney transplant recipients. The study consisted of 199 previously nondiabetic adult kidney transplant recipients who were ≥3 months posttransplantation (one subject was enrolled at 73 days posttransplant). All study subjects were required to have a history of normal FPG (not defined) prior to study entry. Pregnant patients, patients on dialysis and those with recent blood transfusion or blood loss that might affect A1C measurements were excluded. A normal A1C was defined as an A1C of <6.1%. Of 199 patients studied, 20 (10.1%) were found to have an A1C ≥ 6.1%, six of whom had both elevated A1C and new-onset elevated FPG at study entry despite a history of normoglycemia. In clinical follow-up (6.9 years posttransplant), 13 of the 20 (all six patients with both elevated FPG and A1C) and seven of the 14 patients with only elevated A1C had medical intervention for diabetes or glucose intolerance. Of the six patients with elevated A1C and FPG, five were eventually diagnosed with diabetes mellitus at long-term follow-up. Of the 14 patients with elevated A1C and normal screening FPG, three were diagnosed with diabetes mellitus and four with glucose intolerance. Notably, the odds of African Americans having an elevated A1C were 2.8 times higher than those of other
races, with 19.4% of African Americans having elevated A1C compared with 8% of their non-African American counterparts. However, multivariate logistic regression analysis demonstrated that high normal FPG was significantly associated with an elevated A1C ($P = 0.003$), whereas an ethnicity effect was only marginally significant when adjusted for FPG ($P = 0.08$). The investigators concluded that A1C level was a more sensitive test than FPG in detecting NODAT and further validated this recommendation in African Americans. Nonetheless, their study was not without shortcomings. The rationale for using an A1C level of $\geq 6.1\%$ to screen for NODAT was not defined and the number of patients undergoing the gold standard OGTT was not stated. Furthermore, African Americans predominated the study population (81.9%). Hence, the use of A1C as a screening or diagnostic tool in the setting of organ transplantation has yet to be validated.

The utility of FPG and A1C in the selection of patients to undergo OGTT

In a single center study, Valderhaug et al$^{10}$ aimed to assess the accuracy of FPG and A1C for the selection of patients who should undergo a diagnostic OGTT 10 weeks after renal transplantation. Among the 1637 previously nondiabetic renal transplant recipients who were prospectively examined 10 weeks after transplantation, 66 patients were found to have manifest NODAT and were excluded from oral glucose tolerance testing. The remaining 1571 patients with previously normal FPG underwent an OGTT. Of these, 213 (14\%) were diagnosed with NODAT, 51\% of whom (n = 109) were identified by 2-hour PG $\geq 11.1$ mmol/L alone, and 17\% (n = 35) by FPG alone (FPG $\geq 7.0$ mmol/L). Sixty-nine patients (32\%) fulfilled both criteria for NODAT. To assess the diagnostic accuracy of FPG and A1C to predict a 2-hour PG $> 11.1$ mmol/L, an analysis involving a subgroup of patients with a FPG of $< 7$ mmol/L and available A1C levels (n = 929) was performed. Receiver operating characteristic analysis revealed an area under the curve of 0.761 (95\% confidence interval [CI]: 0.714–0.809) for FPG and 0.817 (95\% CI: 0.758–0.876) for A1C. Performing an OGTT on patients with a FPG $\geq 5.3$ mmol/L or A1C $\geq 5.8\%$ predicted diabetes with 81\% and 83\% sensitivity, requiring 49\% and 41\% of the patients to be tested, respectively. The combined criteria of FPG $\geq 5.0$ mmol/L and A1C $\geq 5.7\%$ provided similar sensitivity (79\%) from testing only 29\% of the population. The authors concluded that OGTT should be considered in patients with a FPG between 5.3–6.9 mmol/L or glycosylated hemoglobin $> 5.8\%$ or in those with combined FPG $> 5.0$ mmol/L and A1C $> 5.7\%$. However, the authors acknowledged that 95\% of the study population were white and the study results might not be valid for patients of other ethnicities.

The utility of FPG, A1C, and OGTT in the prediction of NODAT development and as a screening tool: summary of the literature

A literature review suggests that similar to the general population, the 2-hour OGTT diagnostic criteria may be more sensitive in identifying patients with IGT or NODAT than those set for FPG.

The introduction of A1C as an additional optional diagnostic criterion for diabetes mellitus in the general population has sparked interest in its use as a screening and diagnostic tool in renal transplant recipients. One single-center study suggested that A1C level was a more sensitive test than FPG in detecting NODAT, particularly in African Americans (as discussed in the previous section). However, the majority of patients in the study were African Americans. The utility of A1C as the routine screening or diagnostic tool in identifying patients with NODAT has yet to be validated in patients of other ethnic backgrounds. Clinical studies evaluating the utility of FPG, A1C, and OGTT in the prediction of NODAT development and as a screening tool are summarized in Table 2.

Predictive diagnostic tools for NODAT development: perioperative hyperglycemia and diabetes prediction models

New-onset hyperglycemia in the immediate postoperative period

Recently, new-onset hyperglycemia in the immediate postoperative period (inpatient hyperglycemia) defined as bedside capillary glucose of $\geq 200$ mg/dL on at least one measurement, or the administration of insulin therapy at any time during the hospital stay, has been suggested to be predictive of future NODAT risk.$^{11}$ Among 377 primary kidney transplant recipients with at least 1-year follow-up, NODAT developed in 4% of patients without inpatient hyperglycemia, 18% of patients with inpatient hyperglycemia, but not treated with insulin, and in 30% of patients who were diagnosed with inpatient hyperglycemia and treated with insulin. Further studies are required to confirm the utility of new-onset hyperglycemia in the
Table 2 Clinical studies evaluating the utility of FPG, A1C, and OGTT in the screening and diagnosis of NODAT

| Study protocols                                      | Demographic characteristics | Study results                                                                 | Conclusions                                                                 | References |
|------------------------------------------------------|----------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------|
| FPG and OGTT                                         | White 91.4%                | • 17.8% developed NODAT                                                       | A normal FPG (vs diabetic) and a normal OGTT used to identify patients at 1-year prevalence | Kuypers et al |
| N = 359                                              | Blacks 1.4%                | • A normal (vs diabetic) OGTT at day 5 postTx was associated with ↓NODAT risk (OR = 0.03; P = 0.0002) |                                                                 |            |
| All patients completed                               | Arabic 7.2%                | • A normal (vs diabetic) FPG on day 5 postTx was associated with ↓NODAT risk (OR = 0.06; P < 0.0001) |                                                                 |            |
| OGTT 5 days postTx                                    |                            | Sensitivity, 93.4%; Specificity, 71.9%                                      |                                                                 |            |
| Mean follow-up                                       |                            | ROC analyses                                                                  | A negative predictive value of 89.4% suggests normal OGTT may identify patients with a low risk (near 10%) for NODAT |            |
| 42.8 ± 16.9 months                                   |                            | • 16.3% developed NODAT at month 12                                           |                                                                 |            |
| FPG at day 5 postTx                                   |                            | • A fifth day FPG ≥126 mg/dL was associated with a more than fourfold increase in NODAT risk (relative risk: 4.784;  P = 0.002) |                                                                 |            |
|                                                        |                            | The positive and negative predictive values of a fifth day FPG ≥ 126 mg/dL for predicting NODAT at 1-year were 40% and 89.4%, respectively |                                                                 |            |
| FPG                                                  | Spanish study              | ROC analyses                                                                  | A negative predictive value of 89.4% suggests normal OGTT may identify patients with a low risk (near 10%) for NODAT | Rodriguez et al |
| N = 282 (patients with graft survival > 1 year)       |                            | • Optimal FPG predictive of NODAT: 101 mg/dL; 5.6 mmol/L (AUC = 0.70; sensitivity 64%; specificity 67%, positive predictive 20%; negative predictive 93%) |                                                                 |            |
| FPG at day 5 postTx                                   |                            | • Optimal FPG predictive of IGT less well-defined (AUC = 0.54)               |                                                                 | Armstrong et al |
| FPG and OGTT                                          | White > 90%                | • Prevalence of NODAT (OGTT vs FPG 17% vs 6%, respectively; P = 0.0001)      |                                                                 |            |
| N = 188 > 6 months postTx, OGTT performed in patients with FPG < 7.0 mmol/L |                | ROC analyses                                                                  | A negative predictive value of 89.4% suggests normal OGTT may identify patients with a low risk (near 10%) for NODAT |            |
| FPG and OGTT                                          | White 96%                  | OGTT revealed 10% had overt DM, 9% IGT alone, 18% IFG alone, 14% combined IFG and IGT |                                                                 |            |
| N = 122 > 6 months postTx, OGTT performed in patients with two FPG values between 5.6–6.9 mmol/L |                | ROC analyses                                                                  | A negative predictive value of 89.4% suggests normal OGTT may identify patients with a low risk (near 10%) for NODAT |            |
| FPG and A1C                                           | African Americans 81.9%   | ROC analyses                                                                  | A negative predictive value of 89.4% suggests normal OGTT may identify patients with a low risk (near 10%) for NODAT |            |
| N = 199 ≥3 months postTx, all patients had a history of normal FPG prior to study Normal A1C defined as <6.1% |                | • Twenty (10.1%) had A1C ≥ 6.1% (6 of whom had both ↑A1C and new onset ↑FPG at study entry) and 14 had ↑A1C only |                                                                 |            |
| FPG, A1C, and OGTT                                    | White 95%                  | • Of the 6 patients with both ↑A1C and new onset ↑FPG, 5 were diagnosed with NODAT |                                                                 |            |
| N = 929 @ 10-week postTx, Patients who had both FPG < 7.0 mmol/L, and A1C levels available were evaluated |                | • Of the 14 patients with ↑A1C only, 3 were diagnosed with NODAT and 4 with glucose intolerance |                                                                 |            |
|                                                        |                            | • The odds of African Americans having ↑A1C were 2.8 times higher than other races |                                                                 |            |
|                                                        |                            | • High normal FPG was significantly associated with an ↑A1C (P = 0.003)       |                                                                 |            |
|                                                        |                            | • Race effect marginally significant when adjusted for FPG (P = 0.08)         |                                                                 |            |
|                                                        |                            | ROC analyses                                                                  | A negative predictive value of 89.4% suggests normal OGTT may identify patients with a low risk (near 10%) for NODAT |            |
|                                                        |                            | • FPG: AUC 0.761 (95% CI: 0.714–0.809)                                         |                                                                 |            |
|                                                        |                            | • A1C: AUC 0.817 (95% CI: 0.758–0.876)                                        |                                                                 |            |
|                                                        |                            | • Performing OGTT on patients with FPG = 5.3 mmol/L or A1C ≥ 5.8% predicted NODAT with 81% and 83% sensitivity, requiring 49% and 41% of the patients to be tested, respectively |                                                                 |            |
|                                                        |                            | • Combined criterion of FPG ≥ 5.0 mmol/L and A1C ≥ 5.7% provided a sensitivity of 79% from testing 29% of the population |                                                                 |            |
|                                                        |                            | OGTT should be considered in patients with FPG between 5.3–6.9 mmol/L or A1C ≥ 5.8% |                                                                 |            |
|                                                        |                            | In those with combined FPG ≥ 5 mmol/L and A1C ≥ 5.7% |                                                                 |            |
|                                                        |                            | OGTT should be considered in patients with FPG between 5.3–6.9 mmol/L or A1C ≥ 5.8% |                                                                 |            |

Abbreviations: CI, confidence interval; DM, diabetes mellitus; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; PostTx, posttransplant; ROC, receiver-operating characteristic; AUC, area under the curve.
immediate postoperative period in the screening and diagnosis of NODAT.

Diabetes prediction models

Prediction of NODAT before kidney transplant

While most studies designed to predict the development of NODAT predominantly focus on the assessment of actual glucose metabolism, studies in the general population suggested that simple prediction models that incorporate clinical and/or metabolic risk factors (eg, age, family history of type 2 diabetes, body mass index [BMI], blood pressure, high-density lipoprotein [HDL], triglycerides, and IFG) to generate a prediction score may be more effective in predicting diabetes than complex models involving the analysis of glucose metabolism such as OGTT, insulin sensitivity, and/or insulin resistance. Similar comparative studies in the transplant settings are lacking. Nonetheless, studies evaluating the predictive values of diabetic prone clinical factors are emerging.

In one single-center study consisting of 318 nondiabetic patients who subsequently received a kidney transplant, Chakkera et al12 demonstrated that a simple risk score utilizing the sum of seven dichotomized pretransplant risk factors is comparable with that of a standard multivariate model using continuous variables in predicting NODAT (areas under the ROC for predicting NODAT were between 0.7 and 0.72 for all models tested). A score of 0–7 calculated from pretransplant age, family history of type 2 diabetes, BMI, FPG and triglycerides, use of gout medications, and predicted use of posttransplant corticosteroid (nontransplantation settings are lacking). Nonetheless, studies evaluating the predictive values of diabetic prone clinical factors are emerging.

In a retrospective study consisting of 191 kidney transplant recipients with at least 1-year posttransplant follow-up, Rodrigo et al15 showed that the prevalence of NODAT at 1 year increased with increasing number of metabolic syndrome score (0, 0%; 1, 24%; 2, 29%; 3, 31%; 4, 35%; 5, 74%; P = 0.001). Multivariate analysis incorporating the individual metabolic syndrome components as covariates demonstrated that only low-density lipoprotein was independently associated with the development of NODAT.

Prediction of NODAT after the first posttransplant year

In a retrospective analysis consisting of 640 nondiabetic renal transplant recipients, Bayer et al14 demonstrated that the prevalence of NODAT at 1 year increased with increasing number of metabolic syndrome score (0, 0%; 1, 24%; 2, 29%; 3, 31%; 4, 35%; 5, 74%; P = 0.001). Multivariate analysis incorporating the individual metabolic syndrome components as covariates demonstrated that only low-density lipoprotein was independently associated with the development of NODAT.

Table 3 Association of pretransplant risk score with NODAT development

| Risk score* (0–7) | N (# of patients) | 1-year cumulative incidence of NODAT |
|------------------|-------------------|-------------------------------------|
| Low risk (0–1)   | 109               | 13%                                 |
| Intermediate risk (2–3) | 170          | 29%                                 |
| High risk (4–7)  | 39                | 56%                                 |

Notes: *A risk score of 0–7 was calculated from seven pretransplant risk factors (age, family history of type 2 diabetes, BMI, FPG, triglycerides, use of gout medications, and predicted use of steroids posttransplant).

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; NODAT, new-onset diabetes after transplantation.
OGTT in patients with intermediate or normal FPG defined as plasma glucose between 110–125 mg/dL; 6.1–6.9 mmol/L, and normal FPG, defined as FPG < 110 mg/dL (6.1 mmol/L). However, the rationale for performing an OGTT in all patients with FPG < 110 mg/dL (6.1 mmol/L) was not substantiated and such practice may also entail testing a large number of patients, which may not be feasible.

In the authors’ opinion, OGTT should be considered in patients with multiple risk factors for NODAT, whereas FPG or A1C or both can be used to screen or risk stratify patients and should be monitored in all renal transplant recipients at regular intervals. In the case A1C is used, clinicians are advised to confirm that the assays involved have been standardized and validated. Additionally, it should be noted that A1C cannot be accurately interpreted within the first 3 months posttransplantation due to various factors including possible blood transfusions in the early posttransplant period and the presence of anemia or impaired graft function. Blood transfusions may render the test invalid while anemia and kidney impairment can directly interfere with the A1C assay. In islet cell transplant recipients, an artifactual reduction in A1C level has been reported in recipients receiving dapsone for *Pneumocystis carinii* (P. jiroveci) prophylaxis. The cause is unknown but a reduction in red cell lifespan or hemolysis or both has been implicated.

The available literature suggests that similar to the nontransplant settings, the risk for developing NODAT appears to follow a continuum across the entire spectrum of subdiabetic glycemic values. Renal transplant recipients with higher surveillance FPG, higher A1C levels, or both, may convey higher NODAT risk compared with those with lower values and are thus justified to undergo OGTT. Whether all patients with new-onset hyperglycemia in the immediate postoperative period, particularly those requiring insulin, should undergo OGTT at long-term follow-up remains to be studied. Similarly, whether diabetes prediction models can be used to incite further diagnostic testing with an OGTT remains to be explored.

Lastly, it should be noted that the International Expert Committee has recently advocated the use of standardized A1C in the diagnosis of diabetes mellitus in the general population. If A1C testing is not possible, FPG or 2-hour plasma glucose are considered acceptable alternative diagnostic tools. In the United States, OGTT has largely been abandoned outside of screening for gestational diabetes, due to its complexity and low reproducibility. However, in contrast to the nontransplant settings, the use of A1C in the diagnosis of NODAT has not been validated, particularly in the early posttransplant period, due to the presence of multiple confounding factors. Therefore, OGTT has remained the...
gold-standard test for the diagnosis of new-onset diabetes after organ transplantation. A suggested algorithm for NODAT screening is shown in Figure 1.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Starlz TE. Experience in Renal A Transplantation. Philadelphia: Saunders; 1964:111.
2. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International Consensus guidelines. Transplantation. 2003;75(10):SS3–SS24.
3. Wilkinson AH, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19:291–298.
4. Kuypers DR, Claas K, Bammens B, et al. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant. 2008;23:2033–2042.
5. Pham PT, Pham PC. Assessing the risk of post-transplantation diabetes mellitus with an oral glucose tolerance test. Nature Clin Practice. 2008;4(11):600–601.
6. Rodrigo E, Santos L, Pinera C, et al. Early prediction of new-onset diabetes mellitus by fifth-day fasting plasma glucose, pulse pressure, and proteinuria. Transplant Proc. 2011;43(6):2208–2210.
7. Armstrong KA, Prins JB, Beller EM, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol. 2006;1:100–108.
8. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation. 2006;82:1667–1672.
9. Hoban R, Gielda B, Temkit M, et al. Utility of HbA1c in the detection of subclinical post renal transplant diabetes. Transplantation. 2006;81(3):379–383.
10. Valderhaug TG, Jensen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009;88:429–434.
11. Chakker HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010;5:1669–1675.
12. Chakker HA, Weil EJ, Swanson CM, et al. Pretransplant risk score for New-Onset Diabetes After Kidney Transplantation. Am J Transplant. 2011;11:2141–2145.
13. Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of new-onset diabetes after transplantation: 2003 International Consensus guidelines. Transplantation. 2003;75(10):SS3–SS24.
14. Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of new-onset diabetes after transplantation: 2003 International Consensus guidelines. Transplantation. 2003;75(10):SS3–SS24.
15. Bayer ND, Cochetti PT, Kumar MSA, et al. Association of metabolic syndrome with development of new onset diabetes after transplant. Transplantation. 2010;90(8):861–866.
16. Wilson PWE, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–1074.
17. Stern MP, Williams K, Hafifser MM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575–581.
18. Mann DM, Bertoni AG, Shimbo D, et al. Comparative validity of 3 diabetes mellitus risk prediction scoring models in a multiethnic US cohort: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2010;171(9):980–988.
19. Froud T, Faradji RN, Monroy K, et al. Dapsone-induced artificial A1C reduction in islet transplant recipients. Transplantation. 2007;83(6):824–825.

Figure 1 Targeting new onset diabetes after transplantation (NODAT).

Note: Oral Glucose Tolerance Testing (OGTT) is the current gold standard test for the diagnosis of NODAT.

Abbreviations: FPG, fasting plasma glucose; IFG, impaired fasting glucose; NODAT, new-onset diabetes after transplantation.
20. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32(7):1327–1334.
21. Inzucchi SE. Diagnosis of diabetes. *N Engl J Med*. 2012;367(6):542–550.
22. Pham PT, Pham PM, Pham SV; et al. New onset diabetes after transplantation: an overview. *Diabetes Metab Syndr Obes*. 2011;4:175–186.